stoxline Quote Chart Rank Option Currency Glossary
Graphite Bio, Inc. (GRPH)
2.25  -0.02 (-0.88%)    12-08 16:00
Open: 2.26
High: 2.29
Volume: 257,312
Pre. Close: 2.27
Low: 2.24
Market Cap: 130(M)
Technical analysis
2023-12-08 4:43:40 PM
Short term     
Mid term     
Targets 6-month :  2.86 1-year :  3.34
Resists First :  2.45 Second :  2.86
Pivot price 2.29
Supports First :  2.17 Second :  2
MAs MA(5) :  2.27 MA(20) :  2.29
MA(100) :  2.39 MA(250) :  2.53
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  50.3 D(3) :  58.7
RSI RSI(14): 42.3
52-week High :  3.48 Low :  1.59
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GRPH ] has closed above bottom band by 17.7%. Bollinger Bands are 48% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.29 - 2.31 2.31 - 2.32
Low: 2.21 - 2.23 2.23 - 2.24
Close: 2.23 - 2.25 2.25 - 2.27
Company Description

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Headline News

Mon, 04 Dec 2023
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EngageSmart, Inc ... - GlobeNewswire

Fri, 17 Nov 2023
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates ... - Business Wire

Thu, 16 Nov 2023
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WaveDancer, Inc ... - GlobeNewswire

Thu, 16 Nov 2023
2023-11-16 | NDAQ:GRPH | Press Release | Graphite Bio Inc - Stockhouse Publishing

Wed, 15 Nov 2023
GRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to Shareholders - Business Wire

Wed, 15 Nov 2023
LENZ Therapeutics and Graphite Bio Announce Merger Agreement - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 58 (M)
Shares Float 19 (M)
Held by Insiders 9.1 (%)
Held by Institutions 80.1 (%)
Shares Short 1,230 (K)
Shares Short P.Month 1,250 (K)
Stock Financials
EPS -2.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.51
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -17.8 %
Return on Equity (ttm) -48.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.42
Qtrly Earnings Growth 0 %
Operating Cash Flow -67 (M)
Levered Free Cash Flow -48 (M)
Stock Valuations
PE Ratio -1.01
PEG Ratio -0.1
Price to Book value 0.63
Price to Sales 0
Price to Cash Flow -1.97
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android